# Closely watched Pfizer lung cancer drug falls short in clinical trial

> **Open Intelligence Dossier** · First detected: 2026-06-23 15:07 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Closely watched Pfizer lung cancer drug falls short in clinical trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Reuters, Business Wire, Yahoo Finance and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Reuters | Pfizer's experimental drug misses main goal of lung cancer trial | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxOYjhaR2JUWVBWVi1YODRGN0luVlpsQUI4UXNtSzNJcTRSMDllNzdDN0EyUHZMVmV2YXRadjloLW9Pb3Mxc1FYQUxmamFQN2VEM1dBM1BpQ1ZGUmpRTmp0a2J2YjRXcVJETFBFYWIzSTNFV0QzR2U1UlZHTHRPbERKOXAwV29WRHhIcGp6R3YtZkZjb2xqdzVIWDM3TlBvbWRRTHVUXzBzTWZ4SXVPN1R3OUNNY0VJVVBKNEpBUWtRNUpSY0VYVTlYZTlmaDQ?oc=5) |
| Business Wire | Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer | [Source Link](https://news.google.com/rss/articles/CBMingJBVV95cUxPMmN3Y3NfSC14SEZQQWFlaWJmY0pIcGJwNVk0TEctRlRRQm00NGpTOVNRX3JVMURKakU3UUk1R09SalM4RHdIT0ZoR2lzUWlKM3V0ak9MbDFsaWRGZGJxQ2ktZGpuLW1fajY4SmdIRFlLcW1PQVdtcmEtamhpVDNSay1oSlgxaV9IdjNCUXIxOWhVcTVPNEhIcFBiSmVick9sTVlpOU0xM0JyYjRVWHgtNzZDdktyXzVhTjNXOEJwUnM1MzBEOWFIM2NjRkpST2FvNnhpVFpLYTdEOEtvQjgyVmhlY2U4NHFmUkZIcXgxWlZrNVNvdVh2bi1jRVY1ZFZNTXZZWEZmekJlSjZwUzQ4bFJmVjdZNGU1NjJuaGhR?oc=5) |
| Yahoo Finance | PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxOQkE1T3pDZDYxN2g5UWNrRUFSUjVRdGotak9YMTF4VVZhQ3NFMFctREUyZTB6cG5GclVIWW5mWVAzaVVJZE1KTWhPMkluOUp6dlI5ckhXeWVJS2h2S1NITVp6eWxjMGRuQ3A1WnZRNmZpUHEyYjJfUkdIVE5JRlVabVVPUU0wVGRzNzhSZEUtSUJKQmRRVGc?oc=5) |
| Fierce Biotech | Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxPY0JfdnZ0UGY5SWVaalFGaG5JYlZsOWdPbXFDdW5Ra1NPWDJBRFZGRC1kWGhkOUU1NlFkZ3c4bWFXcHhKRGtWUUxsMFBhUmNkeWp2UGQ0bl92aEd3UDBkX3pob0lDVjducTVYaUNuR2p4RmI4cVBUOWR3aGNVNUJEUFVzTnJRTVg1bkJYQkhFMXhqMl9SMTNhU2JYMkp3cUdJRkdpenlR?oc=5) |
| statnews.com | Closely watched Pfizer lung cancer drug falls short in clinical trial | [Source Link](https://news.google.com/rss/articles/CBMif0FVX3lxTE5pZFdpeEltbk92LW1uNm5VekhfUUNja2VjZU01ejN3UG5SeTR6aWxvSkJtZldJVVlSQWtsX3dKX0s4R2wzTW0yVGc1bzdVUjB0cGo2Y0lyZEgwR3RRallWUVI4Ykc2b0dQNTFVQnVxZE1Yc0p1bURVU01Sa0UyR0k?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-06-23/closely-watched-pfizer-lung-cancer-drug-falls-short-in-clinical-trial*